On November 6, 2025, Vigonvita Life Sciences Co., Ltd., (hereinafter referred to as “Vigonvita”) was officially listed on the Main Board of the Hong Kong Stock Exchange (hereinafter referred to as “HKEX”) under the stock code 2630.HK. This marks the beginning of a new journey for Vigonvita in the field of medicine and health.
At the listing ceremony, Dr. Tian Guanghui, Chairman and General Manager of Vigonvita, rang the opening bell to celebrate the company’s successful listing on the Hong Kong stock market. The company’s investors, partners, representatives from the intermediary institutions involved in this IPO, and staff members gathered together to personally witness and celebrate this milestone moment.
Driven by innovation for high-quality development and guided by the mission to improve the health and quality of life for patients and their families, Vigonvita is committed to pioneering new drugs in the fields of neuropsychiatry, reproductive health, and viral infections. The company has established a fully integrated, end-to-end, and internally controlled functional system covering the entire industrial chain from innovative drug lead discovery, druggability optimization and evaluation, and preclinical research, to clinical studies, manufacturing, and clinical application. Within its highly clinically valuable and commercially competitive innovative drug pipeline, two new drugs have already been approved for marketing, four candidate new drugs are in clinical research stages, and three candidate compounds are in the preclinical research stage.
Dr. Tian Guanghui, Chairman and General Manager of Vigonvita, stated: “Vigonvita’s listing on the Hong Kong stock market is a significant milestone in the company’s history. It will bring new capital impetus and lay a solid foundation for the company’s long-term sustainable development. Standing at this new starting point, the company will remain steadfast in its core development philosophy driven by innovation, fully leverage its technological advantages in core areas such as neuropsychiatry, reproductive health, and viral infections, efficiently promote the translation of R&D achievements, address urgent clinical needs, and strive to enhance the health and quality of life for patients globally.”
Acknowledgments
We sincerely thank the government departments, regulatory authorities, partners, and investors at all levels for their trust and support. We are grateful for the professionalism, dedication, and pioneering spirit of all the intermediary institutions that participated throughout this IPO project. Our heartfelt thanks also go to the Vigonvita team for their unwavering belief and relentless efforts.